Journal
BIOMEDICINES
Volume 10, Issue 7, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10071679
Keywords
factor XIa; anticoagulant; thrombosis; bleeding; venom; therapeutic; heparin; LMWH
Categories
Funding
- SINGAPORE NATIONAL RESEARCH COUNCIL (NMRC) Clinician Scientist-Individual Research Grant [CIRG17may014]
- NMRC Open Fund-Young Investigator Research Grant [OFYIRG16may021]
- NMRC Centre Grant [CG21APR1008]
Ask authors/readers for more resources
The study found that Fasxiator can be used as an anticoagulant drug and its inhibition of FXIa is promising. It has the potential to be developed as a FXIa-targeting anticoagulant.
Activated factor XI (FXIa) is an important antithrombotic drug target. Clinical and pre-clinical data have demonstrated that its inhibition attenuates thrombosis with minimal risk of excessive bleeding. We isolated Fasxiator from the venom of banded krait Bungarus fasciatus and subsequently engineered Fasxiator(N17R,L19E), with improved affinity (K-i = 0.9 nM) and selectivity towards FXIa. Here, we assess the in vivo efficacy and bleeding risk of rFasxiator(N17R, L19E) in pre-clinical animal models. Rats injected intravenously (i.v.) with bolus rFasxiator(N17R, L19E) showed the specific in vivo attenuation of the intrinsic coagulation pathway, lasting for at least 60 min. We performed the in vivo dose-ranging experiments for rFasxiator(N17R, L19E) as follows: FeCl3-induced carotid artery occlusion in rats (arterial thrombosis); inferior vena cava ligation in mice (venous thrombosis); tail bleeding time in both rats and mice (bleeding risk). Head-to-head comparisons were made using therapeutic dosages of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) for arterial and venous thrombosis, respectively. In the arterial thrombosis model, 2 mg/kg i.v. rFasxiator(N17R,L19E) achieved a similar antithrombotic efficacy to that of UFH, with >3-fold lower bleeding time. In the venous thrombosis model, the 10 mg/kg subcutaneous (s.c.) injection of rFasxiator(N17R,L19E) achieved similar efficacy and bleeding levels to those of LMWH enoxaparin. Overall, rFasxiator(N17R,L19E) represents a promising molecule for the development of FXIa-targeting anticoagulants.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available